Skip to main content
Smart Investors Daily
Johnson & Johnson logo

NYSE · JNJ

Johnson & Johnson

Healthcare · Drug Manufacturers - General

$267.14

Down-$5.56 (-2.04%)

Updated Nov 20, 2026, 1:03 PM

SID Score

7.8/10

Composite research score

Smart Money

52/100

Neutral

Market cap
505.78B
P/E ratio
20.3
Dividend yield
1.92%
52-week range
$210.50 – $290.25
Volume
9.84M
Avg. volume
8.82M

Price performance · JNJ

JNJ price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 19, 2026

JNJ closed at $267.14 after 21 trading sessions, down 0.18% for the selected period.

Last close
$267.14
Period change
-0.18%
Period low
$263.81
Period high
$285.75
Daily close
View OHLC price history
JNJ OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 19, 2026$269.61$270.60$264.68$267.149.84M
Nov 18, 2026$275.55$278.72$272.58$272.707.94M
Nov 17, 2026$278.99$281.72$277.56$278.708.98M
Nov 16, 2026$288.99$290.2495$282.33$282.558.1M
Nov 13, 2026$285.00$288.11$281.68$285.756.29M
Nov 12, 2026$284.38$286.08$281.00$283.528.81M
Nov 11, 2026$277.96$281.16$276.59$280.415.44M
Nov 10, 2026$282.00$283.2502$279.19$280.787.39M
Nov 9, 2026$278.00$282.7299$276.20$282.116.9M
Nov 6, 2026$267.56$276.41$265.5495$276.228.86M
Nov 5, 2026$278.915$281.92$271.64$272.329.66M
Nov 4, 2026$272.41$277.35$267.67$276.329.62M
Nov 3, 2026$268.51$271.07$265.28$266.176.51M
Nov 2, 2026$272.06$273.0141$267.435$270.568.26M
Oct 30, 2026$280.00$282.015$273.13$273.208.97M
Oct 29, 2026$275.31$278.05$273.595$275.206.02M
Oct 28, 2026$265.83$272.75$264.20$271.046.4M
Oct 27, 2026$265.25$269.09$264.83$268.735.77M
Oct 26, 2026$266.74$272.36$264.97$266.305.78M
Oct 23, 2026$265.82$266.025$262.40$263.815.31M
Oct 22, 2026$260.54$269.67$259.04$267.6110.13M

Latest JNJ news

The latest Smart Investors Daily articles mentioning JNJ.

JNJ research

Overview

Company profile and research snapshot.

Company profile

Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$207.08
Implied upside
—
Analysts
18
JNJ recent ratings
DateFirmRatingTarget
Oct 16, 2026Wells FargoOverweight—
Oct 15, 2026Morgan StanleyOverweight—
Oct 14, 2026Leerink PartnersOutperform—
Oct 14, 2026Wells FargoOverweight—
Oct 14, 2026RBC CapitalOutperform—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Nov 20, 2026

Stock Screening Made Simple: A Closer Look

Stock screening is commonly deployed by investors to 'cut through the noise.' The approach is especially useful when you're choosing from thousands of options, which can often overwhelm investors.

AI research layers

Interpretive context generated from the platform’s current data sources.

Johnson & Johnson Stock Performance

Johnson & Johnson shares closed at $272.70, reflecting a slight daily decline of 0.38% per SID market data. Over the trailing one-month period, the stock has gained $9.82, while the three-month return stands at a more modest $1.93, indicating recent momentum acceleration. On a twelve-month basis, JNJ has appreciated by $27.52, underscoring steady long-term capital appreciation. The stock currently trades above both its 50-day moving average of $267.20 and its 200-day moving average of $250.51, according to Massive/Polygon technical indicators, confirming a sustained uptrend across multiple timeframes. The 14-day relative strength index reads 57.5, positioning JNJ in neutral territory without overbought or oversold conditions. Average daily volume stands at approximately 8.82 million shares. The stock's beta of 0.349 reflects significantly lower volatility than the broader market, consistent with its defensive healthcare sector classification and $505.8 billion market capitalization.

Johnson & Johnson Valuation Analysis

Johnson & Johnson trades at a price-to-earnings ratio of 20.30, according to SID market data, which positions it within a moderate valuation range for large-cap healthcare companies. The PEG ratio stands at 1.91, suggesting the stock is priced at a slight premium relative to its expected earnings growth rate. The company's price-to-book ratio of 6.43 reflects the significant intangible asset base typical of diversified pharmaceutical and medical device conglomerates, per SEC filings. JNJ currently offers a dividend yield of approximately 2.45%, reinforcing its longstanding appeal among income-oriented investors. With a market capitalization of approximately $505.8 billion, Johnson & Johnson remains one of the largest healthcare entities globally. The combination of a sub-0.35 beta and above-market dividend yield highlights the stock's traditional role as a defensive portfolio holding, particularly during periods of elevated broader market volatility and macroeconomic uncertainty.

Smart Money Activity for JNJ

Johnson & Johnson's composite smart money score stands at 52 out of 100, generating a neutral signal per SID market data. Institutional ownership sentiment scores a perfect 25 out of 25, indicating robust conviction among large fund managers and pension funds holding significant JNJ positions, according to 13F institutional filings. Insider activity scores 10.3 out of 25, with SEC Form 4 filings revealing nine insider transactions over the past 90 days — six purchases and three sales — suggesting modestly positive insider sentiment on a net basis. Dark pool activity registers at 9.3 out of 25, reflecting relatively subdued off-exchange institutional trading volumes. Congressional trading activity scores 7.0 out of 25, indicating limited disclosed transactions by members of Congress. The divergence between the maximum institutional score and more moderate readings across other smart money categories explains the overall neutral composite rating. Net insider buying activity remains a constructive datapoint for investors monitoring corporate officer sentiment toward JNJ's forward outlook.

Johnson & Johnson Earnings Outlook

Johnson & Johnson has delivered earnings beats in three of its last four reported quarters, according to company earnings reports. The most recent quarter showed earnings per share of $2.59 against a consensus estimate of $2.53, representing a positive surprise of $0.06. The prior quarter recorded EPS of $2.90 versus estimates of $2.85, a $0.05 beat. The quarter ending April 2026 produced EPS of $2.70, exceeding the $2.67 estimate by $0.03. The only miss occurred in January 2026, when actual EPS of $2.46 fell $0.01 short of the $2.47 consensus, per analyst estimates. The sequential earnings trajectory — from $2.46 to $2.70 to $2.90 — reflects an accelerating quarterly earnings growth pattern. The narrowing surprise margins across quarters suggest analyst models are increasingly calibrated to JNJ's operational performance, reducing the likelihood of significant future earnings deviations in either direction.

Wall Street Analyst Ratings for JNJ

Wall Street consensus on Johnson & Johnson remains firmly constructive, with all five most recent analyst updates maintaining bullish ratings, per SID consensus data. Wells Fargo reiterated its Overweight rating on October 16, 2026, following its earlier Overweight reaffirmation on October 14. Morgan Stanley maintained its Overweight rating on October 15, while Leerink Partners and RBC Capital both reiterated Outperform designations on October 14, according to Wall Street analyst reports. Notably, none of the recent analyst actions involved downgrades or rating changes, with each firm reaffirming prior positive assessments following the latest earnings release. The clustering of reiterations around mid-October aligns with the post-earnings review cycle for the quarter reported on October 13. The unanimity across major bulge-bracket and specialty healthcare research firms reflects broad institutional confidence in JNJ's operational execution. The absence of any Hold or Underweight ratings among recent coverage actions underscores a consensus view favoring continued outperformance.